Aerie Pharmaceuticals to Participate in Two Investor Conferences in June

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.

• Jefferies 2016 Healthcare Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board
  • Presentation Date: Thursday, June 9, 2016
  • Presentation Time: 10:30am E.T.
• JMP Securities Life Sciences Conference 2016
  • Presenter: Richard Rubino, Chief Financial Officer
  • Presentation Date: Wednesday, June 22, 2016
  • Presentation Time: 10:00am E.T.

The presentations will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. It is expected that the NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan™ NDA filing is expected to take place in the second half of 2017.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005048/en/

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
[email protected]
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
[email protected]

Source: Aerie Pharmaceuticals, Inc.

You May Also Be Interested In

• o15 Capital Partners Announces Realization of $31 Million Senior Secured Credit Facility to Simplify Compliance
• STONK Price Prediction: Can STONK 5x Toward $1 After Its 250% Breakout? AlphaPepe Chases the Earlier 100x Setup
• Cyble Appoints Cybersecurity Veteran Steve Ingram as Executive Vice President, US to Lead Market Expansion